Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-09
2005-08-09
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S130100, C424S134100, C424S138100, C424S141100
Reexamination Certificate
active
06927203
ABSTRACT:
The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
REFERENCES:
patent: 4472371 (1984-09-01), Burchiel et al.
patent: 4704692 (1987-11-01), Ladner
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5001225 (1991-03-01), Taylor
patent: 5457048 (1995-10-01), Pasquale et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5585089 (1996-12-01), Queen et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5872223 (1999-02-01), Uckun
patent: 5876949 (1999-03-01), Dreyfuss et al.
patent: 5981245 (1999-11-01), Fox et al.
patent: 2001/0031252 (2001-10-01), Low et al.
patent: 2004/0028685 (2004-02-01), Kinch et al.
patent: 2004/0091486 (2004-05-01), Kinch et al.
patent: WO 93/00425 (1993-01-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/29348 (1994-12-01), None
patent: WO 95/15375 (1995-06-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 00/30673 (2000-06-01), None
patent: WO 00/37500 (2000-06-01), None
patent: WO 01/12172 (2001-02-01), None
patent: WO 01/12840 (2001-02-01), None
patent: WO 01/47892 (2001-07-01), None
patent: WO 03/099313 (2003-12-01), None
patent: WO 2004/014292 (2004-02-01), None
patent: WO 94/11020 (2004-05-01), None
Hill (The Basic Science of Oncology, Tannock et al., Eds, McGraw-Hill, NY, 1992, pp 178-195).
Hartwell et al (Science, 1997, 278:1064-1068.
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
Bowie et al (Science, 1990, 247:1306-1310).
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
On-line Medical Dictionary, Published at the Dept. of Medical Oncology, University of Newcastle upon Tyne Published on Nov. 18, 1997, [retrieved on Jul. 31, 2002] Retrieved from the Internet: <http://www.medical-dictionary.com.
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Becker et al. “Characterization of the SEK-1 receptor tyrosine kinase”FEBS Letters1995;368(2):353-357.
Chen et al. Abstract. “An enhancer element in the EPhA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXA1 and HOXB1 homeobox proteins.”J Biol Chem.1998;273(38):24670-5.
Easty et al. “Loss of Expression of Receptor Tyrosine Kinase Family Genes PTKT and SEK in Metastatic Melanoma”Int. J. Cancer1997;71:1061-1065.
Fox et al. “cDNA cloning and tissue distribution of five human Eph-like receptor protein tyrosine kinases”Oncogene1995; 10(5):897-905.
Kerr et al., ed.LabFax Immunochemistry1994; 115, 157, 191-197.
Larrick et al. (In: Human Hybridomas and Monoclonal Antibodies, Engleman and Foung, Eds. 1985, 8-9).
Martone et al. “Immunolocalization of the receptor tyrosine kinase EphA4 in the adult rat central nervous system”Brain Res.1997;771(2):238-250.
McBride et al. “Ephrin-A1 is expressed at sites of vascular development in the mouse,”Mech. Dev.1998;77(2):201-204. Abstract only.
Muhlbauer et al. Abstract. “Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR”Clinical Cancer Research1999;5(5):1099-1105.
Ohta et al. The receptor tyrosine kinase, Cek8, is transiently expressed on subtypes of motoneurons in the spinal cord during developmentMechanisms Devel.1996;54(1):59-69.
Scully et al. “Isolation and characterization of Desk, a Drosophila eph receptor protein tyrosine kinase,”Mol Cell. Neuro.1999;13(5):337-347.
Wada et al. “Glycosylphosphatidylinositol-anchored cell surface proteins regulate position-specific cell affinity in the limb bud”Devel. Biol.1998;202(2):244-252.
Aasheim et al. “A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes,”Blood.2000;95(1):221-30.
Abrahmsen et al., “Engineering Subtilisin and Its Substrates for Efficient Ligation of Peptide Bonds in Aqueous Solution,”Biochemistry,1991;30:4151-4159.
Andres et al., “Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis,”Oncogene,1994; 9:1463-1467.
Angrist et al. Chromosomal Localization of the Mouse Src-like Adapter Protein (Slap) Gene and Its putative Human Homolog SLA,Genomics,1995;30:623-625.
Baggiolini et al., “Interleukin-8, a chemotactic and inflammatory cytokine,”FEBS Lett.,1992; 307(1):97-101.
Baggliolini et al. “Interleukin-8 and the Chemokine Family”Int. J. Immunopharmae1995; 17(2):103-108.
Behrens et al., “Cell-cell adhesion in invasion and metastasis of carcinomas,”Cancer Treat. Res.,1994; 71:251-266.
Biervert et al. “Semiquantitative expression analysis of ephrine-receptor tyrosine kinase mRNA's in a rat model of traumatic brain injury.”Neurosci Lett.2001; 315(1-2):25-8.
Blanco et al. “Expression of EphA receptors and ligands during chick cerebellar development.”Mech. Dev.2002;114(1-2):225-9.
Bodansky et al., Ed.,Principles of Peptide Synthesis,Springer-Verlag Inc., NY, 1993, Cover pg., Publication pg., and Table of Contents.
Boerner et al. “Production of antigen-Specific Human Monoclonal Antibodies from in vitro-primed Human Splenocytes”,J. Immunol.,1991; 147(1):86-95.
Bohme et al. “PCR mediated detection of a new human receptor-tyrosine-kinase, HEK 2.”Oncogene.1993;8(10):2857-62.
Bovenkamp et al. “Degenerate PCR-based cloning method for Eph receptors and analysis of their expression in the developing murine central nervous system and vasculature”DNA Cell Biol.2001;20(4):203-13.
Brady-Kalnay et al., “Dynamic Interaction of PTPμ with Multiple Cadherins In Vivo”J. Cell. Biol.,1998; 141:287-296.
Brantley et al. “Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.”Oncogene.2002;21(46):7011-26.
Brodeur et al. Mouse-Human Myeloma Partners for the Production of Heterohybridomas,Monoclonal Antibody Production Techniques and Application1987:51-63.
Bruggemann et al., “Designer mice: the production of human antibody repertoires in transgenic animals”Year Immunol.1993; 7:33-40.
Burridge et al., “Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton,”Annu. Rev. Cell Dev. Biol.,1988; 4:487-525.
Burridge et al., “Focal adhesions, contractility, and signaling,”Annu. Rev. Cell Dev. Biol.,1996; 12:463-518.
Carles-Kinch “Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior,”Cancer Research2002;62:2840-2847.
Carter et al. “EphrinA 1-induced cytoskeletal re-organization requires FAK and p130(cas).”Nat Cell Biol.2002;4(8):565-73.
Carter et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci. USA,1992;89:4285-4289.
Chen et al. “An enhancer element in the EphA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXA1 and HOXB1 homeobox proteins.”J Biol Chem.1998;273(38):24670-5.
Chen et al. “Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion.”Oncogene1996;12(5):979-88.
Chen et al., “Integrin-mediated cell adhesion activates mitogen-activated protein kinases,”J. Biol. Chem.,1994;269:26002-26005.
Cheng et al. “Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Fact
Hein Patrick W.
Kinch Michael S.
Zantek Nicole D.
Helms Larry R.
Mueting Raasch & Gebhardt, P.A.
Purdue Research Foundation
Yu Misook
LandOfFree
Treatment of metastatic disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of metastatic disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of metastatic disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3483502